Clinical Trials Logo

Hemophilia A, Severe clinical trials

View clinical trials related to Hemophilia A, Severe.

Filter by:
  • None
  • Page 1

NCT ID: NCT06320626 Recruiting - Child Clinical Trials

Pharmacokinetic-guided Dosing of Emicizumab

DosEmi
Start date: September 8, 2022
Phase: Phase 4
Study type: Interventional

The goal of this multicentre, prospective, open-label, cross-over clinical study is to determine whether individualized PK-guided dosing of emicizumab is non-inferior to conventional dosing of emicizumab in the prevention of bleeding in congenital haemophilia A patients.

NCT ID: NCT05889754 Not yet recruiting - Hemophilia B Clinical Trials

Reliability and Validity of the Turkish Version of the PedHAL

Start date: May 30, 2023
Phase:
Study type: Observational

This study aimed to establish the validity and reliability of the Turkish version of the Pediatric Haemophilia Activities List (short - PedHALshort) questionnaire.

NCT ID: NCT05817812 Recruiting - Clinical trials for Hemophilia A, Severe

A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa

FREEDOM
Start date: July 31, 2023
Phase: Phase 3
Study type: Interventional

FREEDOM is a multicentre, open-label, single-arm, phase 3b study in Europe that aims to enrol approximately 90 previously treated severe haemophilia A patients aged ≥12 years, currently on prophylaxis. After a run-in period of 30-45 days, patients will receive efanesoctocog alfa prophylaxis, 50 IU/kg once-weekly for 24 months (additional preventive dose not permitted). An activity tracker and an electronic patient diary will be used to collect data on physical activity, bleeds, factor dosing, pain, and injuries from screening throughout the study. The primary objective is to describe changes in physical activities over 24 months on efanesoctocog alfa prophylaxis, with a primary endpoint of change from baseline in International Physical Activity Questionnaire (IPAQ) at month 24. Secondary objectives include relationship between physical activity and other variables (bleeds, joint status, pain, injuries, and quality of life); changes in joint status as assessed by HEAD-US, HJHS and MRI; occurrence of bleeds, injuries, pain. Safety and tolerability of efanesoctocog alfa will also be evaluated.

NCT ID: NCT04817462 Recruiting - Clinical trials for Hemophilia A, Severe

Liver Biopsy In Haemophilia Gene Therapy

Start date: August 5, 2022
Phase:
Study type: Observational

To perform a liver biopsy in haemophilia A and B patients stably expressing human FVIII/FIX for a period of at least 6 months following AAV mediated gene transfer. This is to obtain tissue for analysis, to understand if FIX/FVIII transgenic protein expression is mediated by AAV proviral DNA that is integrated into the host cell DNA or if stable expression in humans is mediated by episomal maintained AAV genome.

NCT ID: NCT04754997 Active, not recruiting - Clinical trials for Hemophilia Arthropathy

Effect of Exercise in Pediatric Hemophilia

Start date: January 16, 2021
Phase: N/A
Study type: Interventional

This study investigates the effect of exercise training on pain, physical activity and quality of life in pediatric hemophilia patients.